News headlines about Omeros (NASDAQ:OMER) have been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Omeros earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.5477438314312 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Several equities analysts have weighed in on the company. HC Wainwright set a $30.00 target price on Omeros and gave the company a “buy” rating in a report on Thursday, January 4th. Maxim Group set a $24.00 price target on Omeros and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Wedbush reaffirmed an “outperform” rating and issued a $47.00 price target on shares of Omeros in a research report on Tuesday, November 28th. Zacks Investment Research raised Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 15th. Finally, Cowen downgraded Omeros from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 2nd. Five equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Omeros has an average rating of “Buy” and a consensus target price of $34.14.
Shares of Omeros (NASDAQ OMER) traded down $0.02 during trading hours on Friday, hitting $16.70. The stock had a trading volume of 625,081 shares, compared to its average volume of 639,529. The firm has a market capitalization of $801.66, a P/E ratio of -12.95 and a beta of 3.56. Omeros has a 12 month low of $8.71 and a 12 month high of $27.09. The company has a current ratio of 4.77, a quick ratio of 4.74 and a debt-to-equity ratio of 8.99.
Omeros Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.